Chronic Lymphocytic Leukemia: Expert Insights and Strategies for Refining Patient Care

This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with CLL, featuring education across the disease spectrum enhanced by practical tools for applying new findings in the clinic. All aspects of this program are designed to complement each other and includes an Interactive Treatment Decision Aide, expert-authored modules, expert commentaries, and downloadable slidesets.
Farrukh Awan, MD, MS
John M. Burke, MD
Jeffrey A. Jones, MD, MPH
Jeff P. Sharman, MD
Andrew D. Zelenetz, MD, PhD

ClinicalThought

How should factors such as del(17q) and IgHV mutations be leveraged to individualize treatment in CLL?

Andrew D. Zelenetz, MD, PhD Released: August 9, 2016

How do the latest data affect treatment selection for individual patients with newly diagnosed CLL who do not have specific genetic abnormalities?

Farrukh Awan, MD, MS Released: September 29, 2016

How do the latest clinical data affect treatment selection for patients with relapsed/refractory CLL and the del(17p) genetic abnormality?

Farrukh Awan, MD, MS Released: October 31, 2016

How I incorporate IgHV mutations status in my current clinical practice.

Jeff P. Sharman, MD Released: November 16, 2016

Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure.

Jeffrey A. Jones, MD, MPH Released: January 6, 2017

In the past few years, striking progress has been made in the treatment of ibrutinib-refractory CLL. Read my thoughts on how these promising developments might be applied in your practice.

Farrukh Awan, MD, MS Released: April 13, 2017

Historically, maintenance therapy was considered unnecessary for patients with CLL, but new data may change this practice for some of our patients.

Farrukh Awan, MD, MS Released: May 16, 2017

Among the CLL studies presented at ASCO, these are the 5 that I feel have the most promise to be practice changing in the future.

John M. Burke, MD Released: June 22, 2017

Modules

In this text module with embedded slides, Jeffrey A. Jones, MD, MPH, reviews his approach to treating individual patients with CLL and provides the rationale for his choices.

Jeffrey A. Jones, MD, MPH Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: November 3, 2016 Expired: November 2, 2017

In this downloadable slideset, Jeffrey A. Jones, MD, MPH, reviews his approach to treating individual patients with CLL and provides the rationale for his choices.

Released: November 3, 2016

In this text module with corresponding downloadable slides, Andrew D. Zelenetz, MD, PhD, reviews the latest data behind his strategies for individualizing treatments for diverse patients with CLL.

Andrew D. Zelenetz, MD, PhD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Registered Nurses: 1.7 Nursing contact hours Released: June 15, 2017 Expired: June 14, 2018

In this downloadable slideset, Andrew D. Zelenetz, MD, PhD, reviews the latest data behind his strategies for individualizing treatments for diverse patients with CLL.

Released: June 15, 2017

Chronic Lymphocytic Leukemia: Expert Insights and Strategies for Refining Patient Care

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Recent progress in the management of CLL makes CME and CE very important for medical professionals who care for these patients. Specifically, clinicians must consider multiple factors including the presence of specific cytogenetic markers, patient age, fitness, and comorbidities along with previous treatment history along with the available clinical evidence of safety and efficacy to identify which new targeted therapy or chemoimmunotherapy regimen is most appropriate for their patient.

Through CME and CE, clinicians stay up to date with all the latest research and developments in CLL and learn expert insights to help them apply the recent findings in the clinic to deliver high-quality care and optimize outcomes for patients with CLL.

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
AbbVie
Genentech
Pharmacyclics Inc.
Janssen Biotech, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?